US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab

Oslo, Norway, 1 June 2026 - Lytix Biopharma ASA ("Lytix" or the "Company"), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that clinical data evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma and metastatic triple-negative breast cancer (TNBC) has been  presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, USA. The poster, entitled "Safety and Efficacy of Intratumoral (IT) Ruxotemitide (LTX-315)

Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances

Oslo, Norway, May 21, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) today releases its results for the first quarter of 2026.   Lytix continued to execute on its established development strategy during the first quarter and post-quarter-end period, with progress across its lead asset ruxotemitide and broader oncolytic molecule platform. Clinical development priorities for 2026 and 2027 remain on track, with registrational path planning advancing for ruxotemitide in neoadjuvant melanoma.   Ruxotemitide is supported by a strong and consistent clinical foundation across

Lytix Biopharma: Invitation to the Q1 2026 Results Presentation

Oslo, Norway, May 15, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) will release its first quarter 2026 financial results on Thursday, May 21th, 2026. Join us for a live webcast presentation featuring CEO Øystein Rekdal, CFO Gjest Breistein and CMO Karim Benhadji  where they will discuss the results and provide key insights. Date: Thursday, May 21th, 2026 Time: 14:00 CET Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation. Webcast Details: The

New Phase II Study Data from Lytix Biopharma’s Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma

Oslo, Norway, May 6, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”) today announced that new Phase II clinical data on ruxotemitide, also known as VP-315, will be presented by its partner Verrica Pharmaceuticals Inc. (“Verrica”) at the 2026 Society for Investigative Dermatology SID) Annual Meeting, taking place May 13–16, 2026, in Chicago, Illinois. The data suggests a potential abscopal effect of VP-315 in the treatment of basal cell carcinoma (BCC), as evidenced by reductions in the size of untreated, non-injected lesions. The Phase II data to be presented by Verrica showed:

Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026

Combination therapy demonstrates potential to drive durable anti-tumor responses in difficult-to-treat cancersOslo, Norway, April 21 2026: Lytix Biopharma ASA (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that aggregate data analysis  from its Phase II ATLAS-IT-03 and ATLAS-IT-05 studies evaluating ruxotemitide (LTX-315) in combination with pembrolizumab have been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, taking place May 29 – June 2, 2026 in

Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma

6 patients achieved disease stabilization with several durable responses ongoing at the time of analysis (24 months)Oslo, Norway, April 21, 2026 – Lytix Biopharma ASA (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced final efficacy and safety results from its Phase II ATLAS-IT-05 study evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma who have progressed following prior checkpoint inhibitor therapy. These data were presented at the American

Lytix Biopharma ASA - Conversion to public limited liability company and name change registered

Oslo, Norway, 16 April 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 26 January 2026 regarding the extraordinary general meeting held the same day, at which it was resolved, inter alia, to convert the Company from a private limited liability company (AS) to a public limited liability company (ASA). The conversion and the change of the Company's name to "Lytix Biopharma ASA" has today been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). Disclosure regulation: This

Lytix Biopharma AS: Minutes from Annual General Meeting

Oslo, Norway, 14 April 2026 – The annual general meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held today, 14 April 2026. All proposed resolutions on the agenda were approved. In accordance with the recommendation from the Nomination and Compensation Committee, the general meeting resolved to elect the Board of Directors for a uniform term of two years. The board was reduced from seven to six members, and all board members were elected for a term until the annual general meeting in 2028. The Board of Directors consists of the following members: · Eric Falcand (

Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS

Oslo, 9 April 2026: Lytix Biopharma AS (the “Company”) has granted 100,000 share options to primary insider Darlene Deptula-Hicks, a member of the Company's board of directors, under the Company's long-term incentive program, as approved by the extraordinary general meeting on 26 January 2026.   Each option gives the right to acquire one share in the Company at an exercise price of NOK 9.94. The options are granted without consideration, are subject to vesting over a four-year period, and have a term of five years from the grant date.   Please see the attached notification form

Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth

OSLO, Norway, April 7, 2026 - Lytix Biopharma AS (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced the appointment of Renée Christine Amundsen as Chief Operating Officer (COO), effective immediately. Her appointment comes at a pivotal point as the Company continues to advance its clinical pipeline and sharpen its operational focus for the next stage of growth. Amundsen brings more than 20 years of global leadership experience across the pharmaceutical and life sciences industries. She has led teams and

Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026

Oslo, Norway, 25 March 2026 – The Board of Directors of Lytix Biopharma AS (the “Company”) (Euronext Growth Oslo: LYTIX) hereby calls for the Annual General Meeting to be held at Sandakerveien 138, 0484 Oslo, Norway, on 14 April 2026 at 13:00 hours (CEST).   The agenda for the Annual General Meeting includes, among other items, approval of the Company’s annual report for 2025, election of board members, approval of remuneration to the Board of Directors and the Nomination Committee, and a new board authorization to increase the share capital in connection with the Company’s option

Lytix Biopharma AS: Annual Report for 2025

Oslo, Norway, March 24, 2026 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, has today published its Annual Report for 2025, which was approved by the board of directors on March 23, 2026.  2025 marked a defining year for Lytix, with continued clinical progress, important strategic advancements, and a clearer pathway toward late-stage development and commercialization of its lead candidate, ruxotemitide (formerly LTX-315).  “2025 has been a defining year for Lytix Biopharma,” said Øystein Rekdal, CEO of Lytix Biopharma. “We have

Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026

Final results from the ATLAS-IT-05 study of ruxotemitide (LTX-315) in combination with pembrolizumab to be presented at AACR 2026Oslo, Norway, March 18, 2026: Lytix Biopharma (“Lytix” or the “Company”), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that data from its Phase II ATLAS-IT-05 study evaluating ruxotemitide (LTX-315) in combination with pembrolizumab have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 20–24, 2026 in San Diego, California. The

Lytix Biopharma AS - New share capital registered

Oslo, Norway, 24 February 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 10 February 2026 regarding the results of a subsequent offering of new shares (the "Subsequent Offering"), raising NOK 16,306,227 in gross proceeds.   The share capital increase relating to the Subsequent Offering has been registered today with the Norwegian Register of Business Enterprises. In total, 1,811,803 shares (the "Offer Shares") have been issued through the Subsequent Offering. The Company's new share capital is NOK 7,690,000.50,

Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)

OSLO, Norway, February 17, 2026 — Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, today announced the publication of a review article in the Journal of ImmunoTherapy of Cancer (JITC). The article, “Immunobiological mechanisms of action of oncolytic peptides,” was created in collaboration with the company’s scientific collaborators at the Institut Gustave Roussy (France) and Fox Chase Cancer Center (USA). Bridging the Gap in Cancer Treatment While traditional therapies often struggle with "cold" tumors, or cancers that the immune

Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report

Oslo, Norway, February 12, 2026 – Lytix Biopharma AS (“Lytix” or the “Company”) today published its interim financial report for the second half of 2025 and released its fourth quarter 2025 presentation.   The interim report has been prepared in accordance with IAS 34 and includes financial information for the fourth quarter and the second half of 2025.   Q4 2025 highlights and developments · Positive interim clinical data from the Phase II NeoLIPA neoadjuvant melanoma study were presented by Dr Henrik Jespersen at the Nordic Melanoma Meeting in November 2025. Overall

Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report

Oslo, Norway, February 5, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) will release its fourth quarter 2025 financial results and publish its second half 2025 financial report on Thursday, February 12, 2025.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the Q4 results and provide key insights.   Date: Thursday, February 12, 2025 Time: 10:00 AM CET   Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A

Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy

Oslo, Norway, November 18, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) today releases its results for the third quarter of 2025.Post-quarter-end brought a surge of positive news for Lytix’s first asset, ruxotemitide (formerly LTX-315), with two key clinical results in both neoadjuvant melanoma and basal cell carcinoma (BCC). These findings, outlined below, have prompted the company to accelerate its development plan, focusing on the fastest route to bring the groundbreaking drug to patients. Q3 2025 highlights and developments · Licensing partner Verrica Pharmaceuticals

Lytix Biopharma: Invitation to Q3 2025 Results Presentation

Oslo, Norway, November 14, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) will release its third quarter 2025 financial results on Tuesday, November 18th, 2025.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights.   Date: Tuesday, November 18th, 2025 Time: 10:00 AM CET   Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation.   Webcast

Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital

Investigator-assessed pathologic complete response (pCR) observed in 44% of the first nine evaluable patients (13 total enrolled) and with no relapses reported to date. Oslo, Norway, November 11, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) today announced promising interim results from an ongoing investigator-initiated Phase 2 NeoLIPA study evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab as neoadjuvant therapy in resectable melanoma.Thirteen patients have been enrolled to date, and among the first nine evaluable patients, the combination therapy has

New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide

Oslo, Norway, November 10, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) today announced that new immune response data on ruxotemitide (formerly LTX-315/VP-315) were presented on behalf of Verrica Pharmaceuticals at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland.The immunological analyses from Verrica’s Phase II study in basal cell carcinoma (BCC) demonstrated strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, alongside a marked reduction in immunosuppressive T-regulatory cells in the

Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025

Oslo, Norway, October 8, 2025 – Lytix Biopharma AS, a clinical-stage immuno-oncology company, is pleased to announce that its license partner Verrica Pharmaceuticals Inc. will present new data from its Phase II clinical trial of VP-315 (Ruxotemitide, formerly LTX-315) for the treatment of basal cell carcinoma (BCC) at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5–9, 2025 in National Harbor, Maryland, USA.   VP-315 will be featured in both an oral and a poster presentation during the conference. The abstract, titled “Exploratory

Lytix Biopharma AS: Grant of share options to management and key personnel

Oslo, Norway – 1 September 2025 – Lytix Biopharma AS (the “Company”) announces that the Board of Directors has approved the grant of 4,910,484 share options under the Company’s long-term incentive program.   The grants cover replacement of expired options earlier this year and allocations to strengthen the incentive structure for new and existing members of the management team. The program is designed to attract, retain, and motivate highly qualified talent to drive the Company’s clinical, commercial, and strategic objectives.   “Equity incentives are a key tool for aligning

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe